Optimizing medical management of patients with pre-end-stage renal disease

American Journal of Medicine

Volumn 111, Issue 7, 2001, Pages 559-568

  Pennell, J Phillip ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; CALCITRIOL; CONTRAST MEDIUM; ERYTHROPOIETIN; IRON; LIPID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATE BINDING AGENT; VITAMIN D;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIPID METABOLISM; MORBIDITY; MORTALITY; NEPHROTOXICITY; NUTRITION; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; URINARY TRACT INFECTION;

ANEMIA; COMORBIDITY; DISEASE PROGRESSION; HUMANS; HYPERPARATHYROIDISM; KIDNEY DISEASES; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; NUTRITIONAL STATUS; RENAL DIALYSIS; RISK FACTORS;

EID: 0035173592     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00891-9     Document Type: Review

References (80)

1. NIH Consensus Statement. Morbidity and mortality of dialysis
2. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey
3. Prediction of creatinine clearance from serum creatinine
4. Screening and management of microalbuminuria in patients with diabetes mellitus: Recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation
5. HIV associated nephropathy
6. Strategies for influencing outcomes in pre-ESRD and ESRD patients. A special conference
7. Strategies for influencing outcomes in pre-ESRD, and ESRD patients. A special conference
8. Clinical practice guidelines of the Canadian Society of Nephrology for treatment of patients with chronic renal failure
9. NKF-DOQI clinical practice guidelines for hemodialysis adequacy and peritoneal dialysis adequacy
10. NKF-DOQI clinical practice guidelines for vascular access and anemia of chronic renal failure
11. NKF-DOQI clinical practice guidelines for nutrition in chronic renal failure
12. NKF-DOQI 2000 update. Clinical practice guidelines for hemodialysis adequacy, peritoneal adequacy, vascular access, anemia of chronic renal disease
13. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease
14. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease
15. Molecular insights into renal interstitial fibrosis
16. Preserving renal function in adults with hypertension and diabetes: A consensus approach
17. Blood pressure and end-stage renal disease in men
18. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
19. Hypertension in patients with chronic renal disease
20. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
21. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric non-diabetic nephropathy
22. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet
23. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial
24. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
25. Treatment of the pre-azotemic phases of kidney disease in diabetes
26. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
27. Renoprotective effects of angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy
28. Nonsteroidal anti-inflammatory drugs: Effects on kidney function
29. Nephrotoxic risks of renal angiography: Contrast media-associated nephrotoxicity and atheroembolism - A critical review
30. The effect of acute renal failure on mortality
31. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
32. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM-associated nephropathy
33. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies
34. Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease study
35. Should protein intake be restricted in predialysis patients?
36. Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure
37. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study
38. Controlling the epidemic of cardiovascular disease in chronic renal disease: Report from the National Kidney Foundation Task Force on cardiovascular disease
39. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?
40. Cardiovascular disease: Risk factors, secular trends, and therapeutic guidelines
41. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
42. Hyperlipidemia in patients with chronic renal disease
43. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel of detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel III)
44. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency
45. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE inhibitors
46. Clinical and echocardiographic cardiovascular disease in patients starting end-stage renal disease therapy: Prevalence, associations and prognosis
47. Prolonged therapy with ACE inhibitors induces regression of LVH of dialyzed uremic patients independently from hypotensive effects
48. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
49. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
50. Anemia management in patients with chronic renal insufficiency
51. Cardiovascular effects of recombinant human erythropoietin in predialysis patients
52. Hemodynamic overload in end-stage renal disease patients
53. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States
54. Pharmacokinetics of novel erythropoietin stimulating protein compared with epoietin alfa in dialysis patients
55. Novel erythropoietin stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO)
56. Intravenous iron for the treatment of predialysis anemia
57. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure
58. Pathogenetic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure
59. Prevention of metabolic bone disease in the pre-end-stage renal disease setting
60. Prevention of renal osteodystrophy in predialysis patients
61. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder lowers serum phosphorus and parathyroid hormone
62. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
63. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
64. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
65. Factors causing malnutrition in patients with chronic uremia
66. Protein-energy malnutrition in dialysis patients
67. Effect of nutrition on morbidity and mortality in maintenance dialysis patients
68. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis
69. Spontaneous dietary protein intake during progression of chronic renal failure
70. Dietary protein and energy requirements in ESRD patients
71. Mechanisms causing muscle loss in chronic renal failure
72. Early referral to the nephrologist and timely initiation of renal replacement therapy: A paradigm shift in the management of patients with chronic renal failure
73. Pre-ESRD patient education: A review of the literature
74. Preliminary findings from the national pre-ESRD education initiative
75. Quality of life in chronic dialysis patients: A critical comparison of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis
76. Initiation of dialysis
77. Clinical experience: How much earlier should patients really start renal replacement therapy?